VERTEX PHARMACEUTICALS INC / MA Repayments of Long-term Capital Lease Obligations
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Repayments of Long-term Capital Lease Obligations of $27.93 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermCapitalLeaseObligations · last filed 2019-02-13
- VERTEX PHARMACEUTICALS INC / MA repayments of long-term capital lease obligations for the quarter ending 2018-12-31 was $8.13M, a 76.56% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA repayments of long-term capital lease obligations for the quarter ending 2018-09-30 was $5.73M, a 61.39% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA repayments of long-term capital lease obligations for the quarter ending 2018-06-30 was $4.86M, a 18.03% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA repayments of long-term capital lease obligations for the quarter ending 2018-03-31 was $9.20M, a 95.56% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA repayments of long-term capital lease obligations for fiscal 2018 was $27.93M, a 48.58% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA repayments of long-term capital lease obligations for fiscal 2017 was $18.80M, a 6.81% increase from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA repayments of long-term capital lease obligations for fiscal 2016 was $17.60M, a 11.81% decline from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA repayments of long-term capital lease obligations for fiscal 2015 was $19.95M, a 6.94% decline from fiscal 2014.
| Period end | Repayments of Long-term Capital Lease Obligations 3 month | Repayments of Long-term Capital Lease Obligations 3 month as first filed | Repayments of Long-term Capital Lease Obligations 6 month | Repayments of Long-term Capital Lease Obligations 6 month as first filed | Repayments of Long-term Capital Lease Obligations 9 month | Repayments of Long-term Capital Lease Obligations 9 month as first filed | Repayments of Long-term Capital Lease Obligations 12 month |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $13.87M derived: sum of 2 quarters · filed 2019-02-13 | $18.73M derived: sum of 3 quarters · filed 2019-02-13 | $27.93M 10-K · filed 2019-02-13 | |||
| 2018-09-30 | $5.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $10.60M derived: sum of 2 quarters · filed 2018-10-25 | $19.79M 10-Q · filed 2018-10-25 | $24.40M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2018-06-30 | $4.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $14.06M 10-Q · filed 2018-07-26 | $18.67M derived: sum of 3 quarters · filed 2019-02-13 | $22.22M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2018-03-31 | $9.20M 10-Q · filed 2018-04-27 | $13.80M derived: sum of 2 quarters · filed 2019-02-13 | $17.36M derived: sum of 3 quarters · filed 2019-02-13 | $23.29M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2017-12-31 | $4.61M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $8.16M derived: sum of 2 quarters · filed 2019-02-13 | $14.09M derived: sum of 3 quarters · filed 2019-02-13 | $18.80M 10-K · filed 2019-02-13 | |||
| 2017-09-30 | $3.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $9.48M derived: sum of 2 quarters · filed 2018-10-25 | $14.19M 10-Q · filed 2018-10-25 | $18.45M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2017-06-30 | $5.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $10.64M 10-Q · filed 2018-07-26 | $238.00K 10-Q · filed 2017-07-28 | $14.90M derived: sum of 3 quarters · filed 2019-02-13 | $28.02M derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-03-31 | $4.70M 10-Q · filed 2018-04-27 | $117.00K 10-Q · filed 2017-04-28 | $8.97M derived: sum of 2 quarters · filed 2019-02-13 | $22.09M derived: sum of 3 quarters · filed 2019-02-13 | $22.20M derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2016-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $17.39M derived: sum of 2 quarters · filed 2019-02-13 | $17.49M derived: sum of 3 quarters · filed 2019-02-13 | $17.60M 10-K · filed 2019-02-13 | |||
| 2016-09-30 | $13.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $13.23M derived: sum of 2 quarters · filed 2017-10-30 | $13.33M 10-Q · filed 2017-10-30 | $356.00K 10-Q · filed 2016-10-31 | $33.00M derived: sum of 4 quarters · filed 2018-02-15 | ||
| 2016-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $209.00K 10-Q · filed 2017-07-28 | $19.88M derived: sum of 3 quarters · filed 2018-02-15 | $19.98M derived: sum of 4 quarters · filed 2018-02-15 | |||
| 2016-03-31 | $103.00K 10-Q · filed 2017-04-28 | $19.78M derived: sum of 2 quarters · filed 2018-02-15 | $19.87M derived: sum of 3 quarters · filed 2018-02-15 | $19.97M derived: sum of 4 quarters · filed 2018-02-15 | |||
| 2015-12-31 | $19.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $19.77M derived: sum of 2 quarters · filed 2018-02-15 | $19.86M derived: sum of 3 quarters · filed 2018-02-15 | $19.95M 10-K · filed 2018-02-15 | |||
| 2015-09-30 | $97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $190.00K derived: sum of 2 quarters · filed 2016-10-31 | $281.00K 10-Q · filed 2016-10-31 | $45.44M 10-Q · filed 2015-10-30 | -$23.71M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $184.00K 10-Q · filed 2016-08-01 | $30.29M 10-Q · filed 2015-08-04 | -$23.81M derived: sum of 3 quarters · filed 2017-02-23 | -$8.66M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-03-31 | $91.00K 10-Q · filed 2016-05-03 | $15.15M 10-Q · filed 2015-05-04 | -$23.90M derived: sum of 2 quarters · filed 2017-02-23 | -$8.76M derived: sum of 3 quarters · filed 2017-02-23 | $6.39M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2014-12-31 | -$24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$8.85M derived: sum of 2 quarters · filed 2017-02-23 | $6.30M derived: sum of 3 quarters · filed 2017-02-23 | $21.44M 10-K · filed 2017-02-23 | |||
| 2014-09-30 | $15.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $30.29M derived: sum of 2 quarters · filed 2015-10-30 | $45.44M 10-Q · filed 2015-10-30 | $17.21M 10-Q · filed 2014-11-06 | $46.89M derived: sum of 4 quarters · filed 2016-02-16 | ||
| 2014-06-30 | $15.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $30.29M 10-Q · filed 2015-08-04 | $11.88M 10-Q · filed 2014-07-31 | $31.75M derived: sum of 3 quarters · filed 2016-02-16 | $34.10M derived: sum of 4 quarters · filed 2016-02-16 | ||
| 2014-03-31 | $15.15M 10-Q · filed 2015-05-04 | $2.62M 10-Q · filed 2014-05-05 | $16.60M derived: sum of 2 quarters · filed 2016-02-16 | $18.96M derived: sum of 3 quarters · filed 2016-02-16 | $21.11M derived: sum of 4 quarters · filed 2016-02-16 | ||
| 2013-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $3.81M derived: sum of 2 quarters · filed 2016-02-16 | $5.96M derived: sum of 3 quarters · filed 2016-02-16 | $16.06M 10-K · filed 2016-02-16 | |||
| 2013-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $4.50M derived: sum of 2 quarters · filed 2014-11-06 | $14.60M 10-Q · filed 2014-11-06 | $14.81M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-06-30 | $2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $12.25M 10-Q · filed 2014-07-31 | $12.45M derived: sum of 3 quarters · filed 2015-02-13 | $14.86M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-03-31 | $10.10M 10-Q · filed 2014-05-05 | $10.30M derived: sum of 2 quarters · filed 2015-02-13 | $12.71M derived: sum of 3 quarters · filed 2015-02-13 | $12.71M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2012-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $2.62M derived: sum of 2 quarters · filed 2015-02-13 | $2.62M derived: sum of 3 quarters · filed 2015-02-13 | $2.62M 10-K · filed 2015-02-13 | |||
| 2012-09-30 | $2.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $2.41M derived: sum of 2 quarters · filed 2013-11-07 | $2.41M 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $0.00 10-Q · filed 2013-08-02 | |||||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-08 | ||||||
| 2011-12-31 | $0.00 10-K · filed 2014-02-11 | ||||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |